Search CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Nasdaq · CIK 1187953
Last close0.95
Daily change+0.00 (0.50%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CELZ · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
26.4Momentum
n/aAcceleration
0.0Confidence
64.0Annual Revenue16
Quarterly Revenue52
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality8.1 / 25
Capital Efficiency1.9 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 86.8836%.
ROIC declining · MEDIUMROIC declined by 2828.3728 percentage points.
Key Metrics
Revenue Growth TTM-100%OK
Revenue CAGR 3Y-59.24%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-2,938.14%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y86.88%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $6,000.00 | $3,806.00 | -$6.14M | -$5.86M | n/a | 63.43% | -102,380.23% | n/a | -1,371.6% | 2.38M |
| 2025 FY Dec 31, 2024 | $11,000.00 | $6,600.00 | -$5.74M | -$5.30M | n/a | 60% | -52,216.92% | n/a | -124.69% | 1.48M |
| 2024 FY Dec 31, 2023 | $9,000.00 | $5,400.00 | -$5.62M | -$8.03M | n/a | 60% | -62,445.91% | n/a | -61.58% | 1.41M |
| 2023 FY Dec 31, 2022 | $88,600.00 | $60,109.00 | -$10.24M | -$7.80M | n/a | 67.84% | -11,562.5% | n/a | -229.98% | n/a |
| 2022 FY Dec 31, 2021 | $87,754.00 | $39,805.00 | -$3.13M | -$2.22M | n/a | 45.36% | -3,562.17% | n/a | n/a | 3.25M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $0.00 | sum latest 4 fiscal quarters Revenue | OK | 0001477932-26-004779, 0001477932-25-007978 |
| Revenue Growth TTM | -100% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001477932-26-004779, 0001477932-25-007978 |
| Revenue CAGR 3Y | -59.24% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001477932-26-001517 |
| Revenue CAGR 5Y | -48.43% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001477932-26-001517 |
| Gross Profit CAGR 3Y | -60.14% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001477932-26-001517 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001477932-26-004779, 0001477932-25-007978 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| ROIC | -2,938.14% | NOPAT / Average Invested Capital | OK | 0001477932-26-004779, 0001477932-25-007978 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001477932-26-004779 |
| Current Ratio | 12.91x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001477932-26-004779, 0001477932-25-007978 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001477932-26-001517 |
| Diluted EPS TTM | -$1.46 | Net income TTM / Diluted shares | OK | 0001477932-26-004779, 0001477932-25-007978 |